Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Liabilities and Shareholders Equity: 2021-2024

Historic Liabilities and Shareholders Equity for Abivax (ABVX) over the last 4 years, with Dec 2024 value amounting to $219.3 million.

  • Abivax's Liabilities and Shareholders Equity fell 55.80% to $135.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $836.7 million, marking a year-over-year decrease of 2.74%. This contributed to the annual value of $219.3 million for FY2024, which is 37.68% down from last year.
  • According to the latest figures from FY2024, Abivax's Liabilities and Shareholders Equity is $219.3 million, which was down 37.68% from $351.9 million recorded in FY2023.
  • In the past 5 years, Abivax's Liabilities and Shareholders Equity registered a high of $351.9 million during FY2023, and its lowest value of $79.6 million during FY2022.
  • Its 3-year average for Liabilities and Shareholders Equity is $216.9 million, with a median of $219.3 million in 2024.
  • In the last 5 years, Abivax's Liabilities and Shareholders Equity crashed by 38.40% in 2022 and then spiked by 341.97% in 2023.
  • Over the past 4 years, Abivax's Liabilities and Shareholders Equity (Yearly) stood at $129.3 million in 2021, then tumbled by 38.40% to $79.6 million in 2022, then surged by 341.97% to $351.9 million in 2023, then plummeted by 37.68% to $219.3 million in 2024.